MDWD
MediWound Ltd.
Price Chart
Latest Quote
$14.85
+0.78 (+5.54%)
Current Price
| Previous Close | $14.07 |
| Open | $14.42 |
| Day High | $14.91 |
| Day Low | $14.42 |
| Volume | 26,968 |
Stock Information
| Shares Outstanding | 12.85M |
| Total Debt | $8.13M |
| Cash Equivalents | $44.65M |
| Revenue | $14.48M |
| Net Income | $-26.11M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $190.86M |
| EPS (TTM) | $-2.26 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $154.66M |
| Sales | $14.48M |
| Income | $-26.11M |
| Book/sh | $3.22 |
| Cash/sh | $3.47 |
| Employees | 121 |
Financial Ratios
| Quick Ratio | 2.19 |
| Current Ratio | 2.41 |
| Debt/Eq | 19.62 |
Returns & Margins
| ROA | -23.51% |
| ROE | -71.82% |
| Gross Margin | 19.61% |
| Operating Margin | -541.02% |
| Profit Margin | -180.30% |
Ownership
| Insider Ownership | 15.86% |
| Institutional Ownership | 58.22% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.69 |
| P/S | 13.18 |
| P/B | 4.61 |
Analyst Data
| Recommendation | none |
| Target Price | $30.17 |
Technical Indicators
| SMA20 | $14.15 |
| SMA50 | $15.75 |
| SMA200 | $17.27 |
| RSI | 64.74 |
| ATR | 0.5756 |
| Shares Float | 8.91M |
| Short Float | 14.47% |
| Short Ratio | 17.68 |
| Volatility | 0.15 |
| Rel Volume | 0.75 |
Performance History
| Week | +7.07% |
| Month | -10.43% |
| Quarter | -10.60% |
| 6 Months | -20.88% |
| YTD | -19.38% |
| Year | -21.80% |
| 3 Years | +46.74% |
| 5 Years | -54.08% |
| 10 Years | -72.70% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $14.85 | 91,145 |
| 2026-06-23 | $14.07 | 61,800 |
| 2026-06-22 | $13.96 | 99,400 |
| 2026-06-18 | $14.24 | 69,400 |
| 2026-06-17 | $14.20 | 66,400 |
| 2026-06-16 | $13.87 | 63,900 |
| 2026-06-15 | $13.95 | 64,200 |
| 2026-06-12 | $14.22 | 48,000 |
| 2026-06-11 | $14.09 | 74,800 |
| 2026-06-10 | $13.86 | 69,900 |
| 2026-06-09 | $14.30 | 92,000 |
| 2026-06-08 | $14.21 | 175,200 |
| 2026-06-05 | $14.18 | 64,800 |
| 2026-06-04 | $14.45 | 86,100 |
| 2026-06-03 | $13.73 | 162,900 |
| 2026-06-02 | $13.76 | 111,700 |
| 2026-06-01 | $13.82 | 177,800 |
| 2026-05-29 | $14.33 | 161,700 |
| 2026-05-28 | $14.56 | 237,200 |
| 2026-05-27 | $14.33 | 451,100 |
| 2026-05-26 | $16.68 | 84,900 |
About MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
đ° Latest News
Will MediWound (NASDAQ:MDWD) Spend Its Cash Wisely?
Simply Wall St. âĸ 2026-05-28T12:53:55Z
MediWound Ltd (MDWD) Q1 2026 Earnings Call Highlights: Strategic Collaborations and Revenue ...
GuruFocus.com âĸ 2026-05-27T21:00:25ZMediWound (MDWD) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-27T18:34:34Z
MediWound Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-27T14:06:32Z
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-27T12:10:02Z
NRx Pharmaceuticals, Inc. (NRXP) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-15T21:55:02Z
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-14T23:40:02Z
Journey Medical Corporation (DERM) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-13T21:15:02Z
Profound Medical (PROF) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-07T21:55:07Z
MediWound Q4 Earnings Call Highlights
MarketBeat âĸ 2026-03-06T03:10:05Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $12,133,000 | $16,333,000 | $14,040,000 | $12,333,000 |
| Cost Of Revenue | $13,705,000 | $17,588,000 | $15,108,000 | $13,331,000 |
| Total Revenue | $16,959,000 | $20,222,000 | $18,686,000 | $26,496,000 |
| Operating Revenue | $16,959,000 | $20,222,000 | $18,686,000 | $26,496,000 |
| Expenses | ||||
| Interest Expense | $380,000 | $752,000 | $427,000 | $0 |
| Total Expenses | $42,238,000 | $39,604,000 | $34,187,000 | $34,157,000 |
| Other Income Expense | $753,000 | $-10,746,000 | $7,867,000 | $-9,602,000 |
| Other Non Operating Income Expenses | $13,000 | $-18,000 | - | $-684,000 |
| Net Non Operating Interest Income Expense | $816,000 | $-35,000 | $1,103,000 | $-2,258,000 |
| Total Other Finance Cost | $663,000 | $1,331,000 | $811,000 | $2,528,000 |
| Interest Expense Non Operating | $380,000 | $752,000 | $427,000 | $0 |
| Operating Expense | $28,533,000 | $22,016,000 | $19,079,000 | $20,826,000 |
| Selling And Marketing Expense | $3,869,000 | $3,196,000 | $2,803,000 | $2,039,000 |
| General And Administrative Expense | $10,056,000 | $9,714,000 | $8,574,000 | $8,332,000 |
| Other Operating Expenses | - | - | - | $684,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-23,879,000 | $-30,224,000 | $-6,716,000 | $-19,599,000 |
| Net Interest Income | $816,000 | $-35,000 | $1,103,000 | $-2,258,000 |
| Interest Income | $1,859,000 | $2,048,000 | $2,341,000 | $270,000 |
| Normalized Income | $-24,463,600 | $-21,748,880 | $-12,930,930 | $-12,553,780 |
| Net Income From Continuing And Discontinued Operation | $-23,879,000 | $-30,224,000 | $-6,716,000 | $-19,599,000 |
| Total Operating Income As Reported | $-25,266,000 | $-19,400,000 | $-15,290,000 | $-8,345,000 |
| Net Income Common Stockholders | $-23,879,000 | $-30,224,000 | $-6,716,000 | $-19,599,000 |
| Net Income | $-23,879,000 | $-30,224,000 | $-6,716,000 | $-19,599,000 |
| Net Income Including Noncontrolling Interests | $-23,879,000 | $-30,224,000 | $-6,716,000 | $-19,599,000 |
| Net Income Continuous Operations | $-23,879,000 | $-30,224,000 | $-6,716,000 | $-19,599,000 |
| Pretax Income | $-23,710,000 | $-30,163,000 | $-6,531,000 | $-19,521,000 |
| Interest Income Non Operating | $1,859,000 | $2,048,000 | $2,341,000 | $270,000 |
| Operating Income | $-25,279,000 | $-19,382,000 | $-15,501,000 | $-7,661,000 |
| Depreciation Amortization Depletion Income Statement | $288,000 | $228,000 | $235,000 | $274,000 |
| Depreciation And Amortization In Income Statement | $288,000 | $228,000 | $235,000 | $274,000 |
| Gross Profit | $3,254,000 | $2,634,000 | $3,578,000 | $13,165,000 |
| Special Income Charges | - | - | $211,000 | - |
| Net Income Discontinuous Operations | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-2.10 | $-3.03 | $-0.75 | $-3.93 |
| Basic EPS | $-2.10 | $-3.03 | $-0.75 | $-3.93 |
| Other | ||||
| Tax Effect Of Unusual Items | $155,400 | $-2,252,880 | $1,652,070 | $-1,872,780 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-22,210,000 | $-17,200,000 | $-12,668,000 | $-9,331,000 |
| Total Unusual Items | $740,000 | $-10,728,000 | $7,867,000 | $-8,918,000 |
| Total Unusual Items Excluding Goodwill | $740,000 | $-10,728,000 | $7,867,000 | $-8,918,000 |
| Reconciled Depreciation | $1,860,000 | $1,483,000 | $1,303,000 | $1,272,000 |
| EBITDA (Bullshit earnings) | $-21,470,000 | $-27,928,000 | $-4,801,000 | $-18,249,000 |
| EBIT | $-23,330,000 | $-29,411,000 | $-6,104,000 | $-19,521,000 |
| Diluted Average Shares | $11,376,571 | $9,959,723 | $9,013,144 | $4,987,000 |
| Basic Average Shares | $11,376,571 | $9,959,723 | $9,013,144 | $4,987,000 |
| Diluted NI Availto Com Stockholders | $-23,879,000 | $-30,224,000 | $-6,716,000 | $-19,599,000 |
| Tax Provision | $169,000 | $61,000 | $185,000 | $78,000 |
| Gain On Sale Of Security | $740,000 | $-10,728,000 | $7,656,000 | $-8,918,000 |
| Research And Development | $14,320,000 | $8,878,000 | $7,467,000 | $10,181,000 |
| Selling General And Administration | $13,925,000 | $12,910,000 | $11,377,000 | $10,371,000 |
| Other Gand A | $3,132,000 | $3,147,000 | $3,062,000 | $3,351,000 |
| Salaries And Wages | $6,924,000 | $6,567,000 | $5,512,000 | $4,981,000 |
| Other Special Charges | - | - | $-211,000 | - |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $43,599,000 | $31,054,000 | $31,430,000 | $10,683,000 |
| Total Assets | $86,255,000 | $73,496,000 | $66,459,000 | $50,016,000 |
| Total Non Current Assets | $26,291,000 | $21,333,000 | $16,764,000 | $4,176,000 |
| Other Non Current Assets | $439,000 | $439,000 | $440,000 | $184,000 |
| Non Current Accounts Receivable | $28,000 | - | $233,000 | $180,000 |
| Goodwill And Other Intangible Assets | $33,000 | $99,000 | $165,000 | $231,000 |
| Other Intangible Assets | $33,000 | $99,000 | $165,000 | $231,000 |
| Current Assets | $59,964,000 | $52,163,000 | $49,695,000 | $45,840,000 |
| Prepaid Assets | $359,000 | $458,000 | $722,000 | $287,000 |
| Inventory | $4,093,000 | $2,692,000 | $2,846,000 | $1,963,000 |
| Receivables | $2,372,000 | $5,852,000 | $4,419,000 | $9,695,000 |
| Other Receivables | $751,000 | $1,052,000 | $719,000 | $363,000 |
| Accounts Receivable | $1,621,000 | $4,800,000 | $3,700,000 | $9,332,000 |
| Allowance For Doubtful Accounts Receivable | $-112,000 | $-117,000 | $-6,000 | $-2,000 |
| Gross Accounts Receivable | $1,733,000 | $4,917,000 | $3,706,000 | $9,334,000 |
| Cash Cash Equivalents And Short Term Investments | $53,140,000 | $43,161,000 | $11,866,000 | $33,895,000 |
| Cash And Cash Equivalents | $4,799,000 | $9,155,000 | $11,866,000 | $33,895,000 |
| Cash Financial | $4,799,000 | $9,155,000 | $11,866,000 | $33,895,000 |
| Restricted Cash | - | $34,006,000 | $29,842,000 | $0 |
| Debt | ||||
| Total Debt | $8,152,000 | $6,513,000 | $6,350,000 | $846,000 |
| Long Term Debt And Capital Lease Obligation | $8,152,000 | $6,513,000 | $6,350,000 | $846,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $42,623,000 | $42,343,000 | $34,864,000 | $39,102,000 |
| Total Non Current Liabilities Net Minority Interest | $16,915,000 | $15,802,000 | $16,739,000 | $27,045,000 |
| Other Non Current Liabilities | $8,291,000 | $8,149,000 | $9,933,000 | $10,233,000 |
| Non Current Deferred Liabilities | $0 | $736,000 | $0 | $0 |
| Current Liabilities | $25,708,000 | $26,541,000 | $18,125,000 | $12,057,000 |
| Other Current Liabilities | $13,529,000 | $17,704,000 | $8,706,000 | $2,242,000 |
| Current Deferred Liabilities | $1,181,000 | $457,000 | $24,000 | $63,000 |
| Payables And Accrued Expenses | $10,998,000 | $8,380,000 | $9,395,000 | $9,752,000 |
| Payables | $3,913,000 | $4,408,000 | $5,981,000 | $7,281,000 |
| Other Payable | $220,000 | $226,000 | $1,675,000 | $1,318,000 |
| Accounts Payable | $3,607,000 | $4,096,000 | $4,223,000 | $5,656,000 |
| Derivative Product Liabilities | - | - | $7,296,000 | $15,606,000 |
| Equity | ||||
| Common Stock Equity | $43,632,000 | $31,153,000 | $31,595,000 | $10,914,000 |
| Total Equity Gross Minority Interest | $43,632,000 | $31,153,000 | $31,595,000 | $10,914,000 |
| Stockholders Equity | $43,632,000 | $31,153,000 | $31,595,000 | $10,914,000 |
| Gains Losses Not Affecting Retained Earnings | $-32,000 | $-11,000 | $-18,000 | $-5,000 |
| Retained Earnings | $-228,925,000 | $-205,046,000 | $-174,822,000 | $-168,106,000 |
| Other | ||||
| Ordinary Shares Number | $12,835,185 | $10,793,057 | $9,221,764 | $7,240,020 |
| Share Issued | $12,835,185 | $10,793,057 | $9,221,764 | $7,240,020 |
| Tangible Book Value | $43,599,000 | $31,054,000 | $31,430,000 | $10,683,000 |
| Invested Capital | $43,632,000 | $31,153,000 | $31,595,000 | $10,914,000 |
| Working Capital | $34,256,000 | $25,622,000 | $31,570,000 | $33,783,000 |
| Capital Lease Obligations | $8,152,000 | $6,513,000 | $6,350,000 | $846,000 |
| Total Capitalization | $43,632,000 | $31,153,000 | $31,595,000 | $10,914,000 |
| Foreign Currency Translation Adjustments | $-32,000 | $-11,000 | $-18,000 | $-5,000 |
| Additional Paid In Capital | $272,331,000 | $235,995,000 | $206,251,000 | $178,882,000 |
| Capital Stock | $258,000 | $215,000 | $184,000 | $143,000 |
| Common Stock | $258,000 | $215,000 | $184,000 | $143,000 |
| Employee Benefits | $472,000 | $404,000 | $456,000 | $360,000 |
| Non Current Pension And Other Postretirement Benefit Plans | $472,000 | $404,000 | $456,000 | $360,000 |
| Non Current Deferred Revenue | $0 | $736,000 | $0 | $0 |
| Long Term Capital Lease Obligation | $8,152,000 | $6,513,000 | $6,350,000 | $846,000 |
| Current Deferred Revenue | $1,181,000 | $457,000 | $24,000 | $63,000 |
| Current Accrued Expenses | $7,085,000 | $3,972,000 | $3,414,000 | $2,471,000 |
| Dueto Related Parties Current | $86,000 | $86,000 | $83,000 | $307,000 |
| Net PPE | $25,791,000 | $20,795,000 | $15,926,000 | $3,581,000 |
| Accumulated Depreciation | $-9,415,000 | $-7,930,000 | $-7,136,000 | $-6,463,000 |
| Gross PPE | $35,206,000 | $28,725,000 | $23,062,000 | $10,044,000 |
| Leases | $3,970,000 | $3,451,000 | $3,375,000 | $3,279,000 |
| Machinery Furniture Equipment | $23,164,000 | $18,152,000 | $12,989,000 | $5,550,000 |
| Buildings And Improvements | $8,072,000 | $7,122,000 | - | - |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $2,371,000 | $1,248,000 | $1,851,000 | $1,050,000 |
| Raw Materials | $1,722,000 | $1,444,000 | $995,000 | $913,000 |
| Other Short Term Investments | $48,341,000 | $34,006,000 | $29,675,000 | $0 |
| Other Properties | - | - | $6,698,000 | $1,215,000 |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | - | $417,000 |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-21,626,000 | $-19,897,000 | $-16,929,000 | $-12,440,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-16,121,000 | $-13,624,000 | $-10,465,000 | $-11,885,000 |
| Cash Flow From Continuing Operating Activities | $-16,121,000 | $-13,624,000 | $-10,465,000 | $-11,885,000 |
| Operating Gains Losses | $-2,178,000 | $10,721,000 | $-8,038,000 | $11,522,000 |
| Cash From Discontinued Operating Activities | - | - | - | $0 |
| Investing Activities | ||||
| Capital Expenditure | $-5,505,000 | $-6,273,000 | $-6,464,000 | $-555,000 |
| Investing Cash Flow | $-17,950,000 | $-8,397,000 | $-34,321,000 | $-481,000 |
| Cash Flow From Continuing Investing Activities | $-17,950,000 | $-8,397,000 | $-34,321,000 | $-481,000 |
| Cash From Discontinued Investing Activities | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $27,416,000 | $22,165,000 | $24,909,000 | $38,380,000 |
| Financing Cash Flow | $29,620,000 | $19,394,000 | $22,917,000 | $35,764,000 |
| Cash Flow From Continuing Financing Activities | $29,620,000 | $19,394,000 | $22,917,000 | $35,764,000 |
| Net Other Financing Charges | $-1,426,000 | $-3,981,000 | $-1,992,000 | $-2,626,000 |
| Net Common Stock Issuance | $27,416,000 | $22,165,000 | $24,909,000 | $38,380,000 |
| Common Stock Issuance | $27,416,000 | $22,165,000 | $24,909,000 | $38,380,000 |
| Other | ||||
| End Cash Position | $4,799,000 | $9,155,000 | $11,866,000 | $33,895,000 |
| Beginning Cash Position | $9,155,000 | $11,866,000 | $33,895,000 | $11,046,000 |
| Effect Of Exchange Rate Changes | $95,000 | $-84,000 | $-160,000 | $-549,000 |
| Changes In Cash | $-4,451,000 | $-2,627,000 | $-21,869,000 | $23,398,000 |
| Proceeds From Stock Option Exercised | $3,630,000 | $1,210,000 | $0 | $10,000 |
| Interest Received Cfi | $1,591,000 | $2,252,000 | $1,947,000 | $74,000 |
| Net Investment Purchase And Sale | $-14,036,000 | $-4,376,000 | $-29,804,000 | $0 |
| Net PPE Purchase And Sale | $-5,505,000 | $-6,273,000 | $-6,464,000 | $-555,000 |
| Purchase Of PPE | $-5,505,000 | $-6,273,000 | $-6,464,000 | $-555,000 |
| Change In Working Capital | $4,767,000 | $1,270,000 | $2,336,000 | $-7,244,000 |
| Change In Payables And Accrued Expense | $1,254,000 | $923,000 | $-1,522,000 | $695,000 |
| Change In Payable | $1,254,000 | $923,000 | $-1,522,000 | $695,000 |
| Change In Account Payable | $2,350,000 | $406,000 | $-594,000 | $414,000 |
| Change In Inventory | $-1,363,000 | $187,000 | $-906,000 | $-721,000 |
| Change In Receivables | $4,876,000 | $-1,021,000 | $4,764,000 | $-7,218,000 |
| Changes In Account Receivables | $3,211,000 | $-1,141,000 | $5,658,000 | $-7,582,000 |
| Other Non Cash Items | $201,000 | $-12,000 | $-1,290,000 | $218,000 |
| Stock Based Compensation | $3,108,000 | $3,138,000 | $1,940,000 | $1,946,000 |
| Depreciation Amortization Depletion | $1,860,000 | $1,483,000 | $1,303,000 | $1,272,000 |
| Depreciation And Amortization | $1,860,000 | $1,483,000 | $1,303,000 | $1,272,000 |
| Pension And Employee Benefit Expense | $31,000 | $-30,000 | $83,000 | $109,000 |
| Gain Loss On Investment Securities | $-2,158,000 | $10,704,000 | $-8,310,000 | $10,888,000 |
| Net Foreign Currency Exchange Gain Loss | $-51,000 | $47,000 | $189,000 | $525,000 |
| Net Income From Continuing Operations | $-23,879,000 | $-30,224,000 | $-6,716,000 | $-19,599,000 |
| Change In Other Working Capital | - | $1,181,000 | - | - |
| Sale Of Investment | - | - | - | $0 |
Fetched: 2026-06-22